MindMaze Therapeutics Holding SA (SIX: MMTX) announced the results of its Annual General Meeting held on June 25, 2026, in Geneva, Switzerland. Shareholders voted on all proposals submitted by the Board of Directors, approving most but rejecting the proposed increase in conditional share capital, which did not obtain the required qualified majority.
The board saw changes with the re-election of Walid Hanna, Olaf Blanke, and Martin Reiss, and the election of Brad Hollinger, Founder, Chairman and Chief Executive Officer of Vibra Healthcare, and Zach Henderson, Chief Executive Officer of MindMaze Therapeutics, as new members. Shareholders also approved the 2025 Annual Report and financial statements, appropriation of available earnings, discharge of board and executive committee members, and the re-election of Walid Hanna as Chairman. Additionally, they approved elections to the Nomination and Compensation Committee, re-election of the Independent Proxy and statutory auditor, compensation proposals for the Board and Executive Committee, and the consultative vote on the 2025 Compensation Report.
The rejection of the conditional share capital increase is significant as it may impact the company's ability to raise capital through equity issuance in the future. However, the approval of other proposals indicates shareholder confidence in the company's direction. Detailed voting results will be published on the Company’s website later today, and further information is available in the AGM Invitation.
MindMaze Therapeutics, a global leader in scalable precision neurotherapeutics, focuses on redefining recovery for patients with neurological disorders. The company integrates advanced software, proprietary sensors, and AI-driven data analytics to provide a continuum of care from acute hospital to home therapy. Its FDA-cleared and CE-marked products address shortages of specialized clinicians and offer scalable solutions for stroke, Parkinson’s disease, and other conditions. With rigorous clinical validation and a robust R&D pipeline, the company aims to operationalize neurorestorative medicine. More information is available at www.mindmazetherapeutics.com.
The outcomes of this AGM are important for shareholders and the broader medical community as they shape the company's governance and financial strategy. The new board members bring expertise from healthcare and company leadership, potentially influencing future innovations and partnerships. The failed capital increase may lead to alternative financing strategies, affecting the pace of product development and commercialization.
